| Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT … V Grattan, AR Vaino, Z Prensky, MS Hixon ACS omega 4 (9), 14151-14154, 2019 | 15 | 2019 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent 10,259,786, 2019 | 5 | 2019 |
| A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 … L Biernat, VT Grattan, MS Hixon, Z Prensky, AR Vaino Psychopharmacology 239 (9), 3009-3018, 2022 | 3 | 2022 |
| Psychotrophic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent 10,167,256, 2019 | 3 | 2019 |
| Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic (P. 101) AR Vaino, VT Grattan, Z Prensky, MS Hixon receptor 2, 3, 2019 | 2 | 2019 |
| Pre-clinical evaluation of two novel benzamides LB–102 and 103 for the treatment of schizophrenia JC Neill, B Grayson, G Podda, D Cadinu, M Beconi, V Grattan, MS Hixon, ... The AAPS Journal (Poster) 16, 1247-1258, 2017 | 2 | 2017 |
| P. 0830 LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies A Vaino, A Mintz, A Eramo, N Caito, G Chand, G Nicol, M Hixon, V Grattan, ... European Neuropsychopharmacology 53, S606, 2021 | 1 | 2021 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent 11,040,943, 2021 | 1 | 2021 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent 10,689,338, 2020 | 1 | 2020 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent App. 18/335,877, 2024 | | 2024 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent App. 18/389,711, 2024 | | 2024 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent App. 18/516,614, 2024 | | 2024 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent 11,713,295, 2023 | | 2023 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent 11,377,421, 2022 | | 2022 |
| PET Clinical Study of Novel Antipsychotic LB-102 Demonstrates Unexpectedly Prolonged Dopamine Receptor Target Engagement D Wong, A Eramo, N Caito, G Chand, G Nicol, M Hixon, L Tian, E Lessie, ... NEUROPSYCHOPHARMACOLOGY 46 (SUPPL 1), 345-345, 2021 | | 2021 |
| P. 467 Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2/5-HT7 antagonist, in healthy volunteers A Vaino, VT Grattan, Z Prensky, MS Hixon, L Biernat European Neuropsychopharmacology 40, S265, 2020 | | 2020 |
| Real-time LB-102 target engagement using [11C] Raclopride PET A Molotkov, M Doubrovin, M Dolan, S Joseph, A Vaino, Z Prensky, A Mintz Journal of Nuclear Medicine 61 (supplement 1), 79-79, 2020 | | 2020 |
| Psychotropic agents and uses thereof AR Vaino, VT Grattan, Z Prensky US Patent App. 16/383,933, 2020 | | 2020 |
| LB-102, a potential schizophrenia treatment, displays polypharmacology as a racemate—S enantiomer binds D2 and D3 and R binds 5-Ht7 A Vaino, Z Prensky, M Hixon, V Grattan European Neuropsychopharmacology 29, S246-S247, 2019 | | 2019 |
| LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies (P. 0830) AR Vaino, A Mintz, A Eramo, N Caito, GB Chand, G Nicol, MS Hixon, ... receptor 2, 3, 0 | | |
